NitroMed to Present at the 12th Annual Future Leaders in the Biotech I

    Business Editors/Medical Editors
    BIOWIRE2K
    BioCentury Future Leaders in the Biotech Industry Conference

    LEXINGTON, Mass.--(BUSINESS WIRE)--March 31, 2005--NitroMed, Inc. (NASDAQ: NTMD) today announced that its President and CEO, Michael D. Loberg, Ph.D., will present an overview of the Company at the BioCentury Future Leaders in the Biotech Industry conference on Thursday, April 7th at 2:30 pm eastern time at the Millennium Broadway Hotel & Conference Center in New York City.
    The presentation will be webcast live and may be accessed via the NitroMed website at www.nitromed.com. The presentation will be archived on the NitroMed website for one week after the presentation.

    About NitroMed, Inc.

    NitroMed is an emerging pharmaceutical company focused on the research, development and commercialization of proprietary pharmaceuticals based on the therapeutic benefits of the naturally occurring molecule nitric oxide. The Company uses its expertise in nitric oxide biology and chemistry in an effort to develop both new pharmaceuticals, as well as safer, more effective versions of existing drugs. Research and development efforts focus on major diseases that are characterized by a deficiency in nitric oxide, such as cardiovascular and inflammatory diseases. BiDil, the Company's lead product candidate, is an orally administered nitric oxide-enhancing medicine being developed for the treatment of heart failure in African Americans. Corporate collaborations are also an element of the Company's business strategy, and NitroMed has an agreement with Boston Scientific to jointly develop nitric oxide-enhanced cardiovascular stents.

    Forward Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the Company, including statements regarding the Company's drug candidate BiDil, its financial forecasts, its future development plans, as well as statements containing the words "believe," "anticipate," "plan," "expect," "will," "may," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: difficulties or delays relating to required regulatory approvals to develop, market and sell BiDil and the Company's other products under development; the Company's ability to successfully complete clinical trials of its products under development; the Company's dependence on corporate collaborators to develop, manufacture, market and sell products based upon its technologies; the Company's failure to obtain or maintain intellectual property protection and required licenses for its technologies and products under development; the Company's ability to obtain the substantial additional funding required to conduct research and development, manufacturing, marketing and sales of its products under development; and other factors discussed in its Quarterly Report on Form 10-K for the year ended December 31, 2004, which is filed with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

--30--JO/bo*

CONTACT: NitroMed, Inc. Lawrence E. Bloch, M.D., J.D., 781-266-4197 Chief Financial Officer and Chief Business Officer

KEYWORD: MASSACHUSETTS NEW YORK TRACK INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY TRADESHOW CONFERENCE CALLS SOURCE: NitroMed, Inc.

Copyright Business Wire 2005